Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
Argus Health

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,250,113

« Back to Dashboard

Summary for Patent: 4,250,113

Title: Chemical compounds
Abstract:Compounds of the formula: ##STR1## wherein R represents the group --CH.sub.2 CH.sub.2 OH or --CH.sub.2 CHOHCH.sub.2 OH, particularly in racemic or optically active form, are employed as active ingredients in X-ray contrast agents for intracerebral, but particularly for vascular use. The compounds are prepared by reacting 5-(N-acetamido)-2,4,6-triiodo-N,N'-bis-(2,3-dihydroxypropyl)isophthalamide or an O-acetyl derivative thereof with an appropriate hydroxyalkylating agent and subsequently, if necessary, hydrolysing any unwanted O-acetyl groups.
Inventor(s): Nordal; Vegard (Oslo, NO), Holtermann; Hugo (Oslo, NO)
Assignee: Nyegaard & Co. A/S (Oslo, NO)
Application Number:06/069,589
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 4,250,113

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom24338/76Jun 11, 1976

International Patent Family for Patent: 4,250,113

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Belgium855580► Subscribe
Switzerland630064► Subscribe
Germany2726196► Subscribe
Denmark258477► Subscribe
Denmark150504► Subscribe
France2354316► Subscribe
United Kingdom1548594► Subscribe
Hong Kong56683► Subscribe
JapanS5321137► Subscribe
JapanS5654310► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Argus Health
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus